IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
This study has been completed.
Sponsor:
German Breast Group
Collaborators:
Amgen
Roche Pharma AG
TEVA
Vifor Pharma
Information provided by (Responsible Party):
German Breast Group
ClinicalTrials.gov Identifier:
NCT02125344
First received: April 22, 2014
Last updated: July 10, 2017
Last verified: July 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | January 30, 2017 |
| Primary Completion Date: | November 2016 (Final data collection date for primary outcome measure) |